|
Published by: Datamonitor
Published: Nov. 15, 2001 - 121 Pages
Table of Contents
DATAMONITOR HEALTHCARE
EXECUTIVE SUMMARY
Scope
Datamonitor insight into the Alzheimer's disease market
Key metrics
TABLE OF CONTENTS
ALZHEIMER'S DISEASE MARKET DEFINITION
Market definition
Therapy classes covered
Alzheimer's disease indications
Epidemiology overview
Alzheimer's disease drug class definitions
Acetylcholinesterase Inhibitors
Definition of gold standard drug
GLOBAL MARKET ANALYSIS
Acetylcholinesterase Inhibitors
Overview of the global AChE inhibitors market
Key trends in the global AChE inhibitors market
Comparison of key brands in AChE inhibitors
Aricept
Exelon
Reminyl
COUNTRY ANALYSIS
Significance of major countries in the global market
Overview of the global Alzheimer's disease market
Breakdown of the country markets by AChE inhibitors
Summary of global market factors
US
Europe
Japan
Summary of AChEI reimbursement
The US Alzheimer's disease market
Environmental drivers in the US
Japan Alzheimer's disease analysis
Environmental drivers in Japan
France Alzheimer's disease analysis
Environmental drivers in France
Germany Alzheimer's disease analysis
Environmental drivers in Germany
Italy Alzheimer's disease analysis
Environmental drivers in Italy
Spain Alzheimer's disease analysis
Environmental drivers in Spain
UK Alzheimer's disease analysis
Environmental drivers in the UK
LIFECYCLE MANAGEMENT
Global drug class lifecycle in Alzheimer's disease
Reformulations in Alzheimer's disease
New indications for Alzheimer's disease drugs
Lifecycle management case studies
Co-marketing strategies in Spain and in Italy
Launch of Reminyl on the AD market
The role of pharmacoeconomics in AD
THE FUTURE DECODED
Market forecasting methodology
Alzheimer's disease market growth
Alzheimer's disease drug class growth
Individual drug growth
Trends in the Alzheimer's disease market to 2008
Market forecast
Drug class forecast
Product forecasts
Alternative forecast scenarios
Summary of major future market drivers
Scenario 1: AChEIs worst case scenario
Scenario 2: AChEIs best case scenario
Scenario 3: Steady growth
Summary of scenario forecasts
APPENDIX
Datamonitor's Central Nervous System Business Unit
Contributing experts
Table of tables
References
Websites
Sales data research methodology
Introduction
Hypothesis formulation
Hypothesis testing
Data verification with key contacts
Quality control
Quantification of data reliability
Confidence ratings
Exchange rates
Patent data
AbstractThe lack of promising pipeline products in phase III development for Alzheimer's disease (AD) has reinforced the stronghold of the few companies that have brought products to the market. This report provides an insightful summary of the AD market in 2000, including global and country specific sales analysis, market drivers, strategic recommendations, and lifecycle management strategies. The report also includes sales forecasts for the entire market by class and individual drugs. Extra insight into the current and future AD market is provided by six key opinion leader interviews.
Get Full Details About This Report >>
|
